In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8

Renard, Dimitri; Collombier, Laurent; Castelli, Christel; Pouget, Jean-Pierre; Kotzki, Pierre‐Olivier; Boudousq, Vincent

doi:10.1186/s12883-016-0630-3

Cited by 7 publications

(4 citation statements)

References 13 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, it should be noted that previous fluorodeoxyglucose (FDG)-positron emission tomography (PET) have reported patterns of decreased metabolism in DM1 brains, particularly in frontotemporal areas (Weber et al, 2010;Renard et al, 2016;Peric et al, 2017). This is in apparent contrast with our hypothesis.…”

Section: Discussioncontrasting

confidence: 99%

Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1

Serra

Scocchia

Meola³

et al. 2020

Cortex

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 99%

Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1

Serra

Scocchia

Meola³

et al. 2020

Cortex

View full text Add to dashboard Cite

show abstract

“…52,95,97,98 Renard and colleagues reported a frontal bilateral reduction in FDG uptake, while no differences were observed in deep GM structures. 99 In a recent study Peric and colleagues, excluding congenital and late-onset patients, detected hypometabolism in frontotemporal regions and a correlation between right frontotemporal glucose uptake and executive function. 100 SPECT investigation revealed that CBF and perfusion were reduced in DM1, mainly in the frontotemporal region.…”

Section: Neuromuscular Disease With Brain Involvementmentioning

confidence: 96%

Advances in imaging of brain abnormalities in neuromuscular disease

Angelini

Pinzan

2019

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries ( Pubmed, Scopus and Google Scholar) including the more common forms of muscular dystrophies such as dystrophinopathies, dystroglycanopathies, myotonic dystrophies, facioscapulohumeral dystrophy, limb-girdle muscular dystrophy, congenital myotonia, and congenital myopathies. A consistent, widespread cortical and subcortical involvement of grey and white matter was found. Abnormalities in the functional connectivity in brain networks and metabolic alterations were observed with positron emission tomography (PET) and single photon emission computed tomography (SPECT). Pathological brain changes with cognitive dysfunction seemed to be frequently associated in NMDs. In particular, in congenital muscular dystrophies (CMDs), skeletal muscular weakness, severe hypotonia, WM abnormalities, ventricular dilatation and abnormalities in cerebral gyration were observed. In dystroglycanopathy 2I subtype (LGMD2I), adult patients showed subcortical atrophy and a WM periventricular involvement, moderate ventriculomegaly, and enlargement of subarachnoid spaces. Correlations with clinical features have been observed with brain imaging characteristics and alterations were prominent in congenital or childhood onset cases. In myotonic dystrophy type 2 (DM2) symptoms seem to be less severe than in type 1 (DM1). In Duchenne and Becker muscular dystrophies (DMD, BMD) cortical atrophy is associated with minimal ventricular dilatation and WM abnormalities. Late-onset glycogenosis type II (GSD II) or Pompe infantile forms are characterized by delayed myelination. Only in a few cases of oculopharyngeal muscular dystrophy (OPMD) central nervous system involvement has been described and associated with executive functions impairment.

show abstract

“…Mielke et al found reduced uptake in all cortical and subcortical regions, predominantly in frontal regions and lentiform nucleus ( 64 ), and Annane et al confirmed these results and reported a negative correlation between glucose consumption and CTG repeat length and plasma insulin levels, reflecting peripheral insulin resistance ( 65 ). Renard et al reported—albeit not corrected for partial volume correction—bilateral symmetrical reduced FDG uptake in the lateral part of the frontal lobes, affecting most severely Brodmann area 8 (related to eye movement control), while deep GM structures did not show reduced metabolism ( 67 ). CTG repeat length did not correlate with hyopmetabolism, although there was a tendency toward lower FDG uptake with CTG repeat length >1000 and early (childhood) onset DM1, congenital cases were not included.…”

Section: Introductionmentioning

confidence: 99%

Current Progress in CNS Imaging of Myotonic Dystrophy

2018

View full text Add to dashboard Cite

Neuroimaging in myotonic dystrophies provided a major contribution to the insight into brain involvement which is highly prevalent in these multisystemic disorders. Particular in Myotonic Dystrophy Type 1, conventional MRI first revealed hyperintense white matter lesions, predominantly localized in the anterior temporal lobe. Brain atrophy and ventricle enlargement were additional early findings already described almost 30 years ago. Since then, more advanced and sophisticated imaging methods have been applied in Myotonic Dystrophy Types 1 and 2. Involvement of actually normal appearing white matter and widespread cortical affection in PET studies were key results toward the recognition of diffuse and not only focally localized brain pathology in vivo. Later, structural abnormalities of both, gray and white matter, have been found in both forms of the disorder, albeit more prominent in myotonic dystrophy type 1. In Type 1, a consistent widespread cortical and subcortical involvement of gray and white matter affecting all lobes, brainstem and cerebellum was observed. Spectroscopy studies gave additional evidence of neuronal and glial damage in both types. Central questions regarding the origin and spatiotemporal evolution of the CNS involvement and its relevance for clinical symptoms had already been raised 30 years ago, however are still not answered. Results of correlation analyses between neuroimaging and clinical parameters are diverse and with few exceptions not well reproducible across studies. It may be related to the fact that most of the reported studies included only small numbers of subjects, sometimes even not separating Myotonic Dystrophy Type 1 from Type 2. But this heterogeneity may also support the current point of view that the clinical impairments are not simply linked to specific and regionally circumscribed structural or functional brain alterations. It seems more convincing that disturbed networks build the functional and structural substrate of clinical symptoms in these disorders as it is proposed in other neuropsychiatric diseases. Consecutively, structural and functional network analyses may provide additional information regarding the link between brain pathology and clinical symptoms. Up to now, only cross-sectional neuroimaging studies have been published. To analyze the temporal evolution of brain affection, longitudinal studies are urgently needed, and systematic natural history data would be useful to identify potential biomarkers for therapeutic studies.

show abstract

In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8

Cited by 7 publications

References 13 publications

Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1

Ventral tegmental area dysfunction affects decision-making in patients with myotonic dystrophy type-1

Advances in imaging of brain abnormalities in neuromuscular disease

Current Progress in CNS Imaging of Myotonic Dystrophy

Contact Info

Product

Resources

About